We are hiring!

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN. 

A significant number of psoriatic patients with severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.

Share the Post:

Related Posts

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors...

World Lupus Day was celebrated on 10th May. At Inhibitec we were very proud to share our progress on the effects of BAMBI deficiency in...

Inhibitec’ s team had the privilege to participate in BIOSPAIN 2023, one of the main international biotechnology events in southern Europe, held in Barcelona. This...

Scroll to Top